Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
Both JNJ and ABBV expect their sales and profits to improve in 2025.
2 Bulletproof Dividend Stocks to Buy in May
Dividend stock investing has long been a cornerstone for building wealth, offering investors a steady stream of passive income while providing a buffer against market volatility.
J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports
HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco Wholesale NASDAQ: COST, and NASDAQ NASDAQ: NDAQ have each announced meaningful hikes to their quarterly payouts, reinforcing their commitment to shareholder value even amid broader market volatility.
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.
Dividend Kings Face-Off: Johnson & Johnson (JNJ) Vs. Procter & Gamble (PG)
If you are someone who thinks investments should generate regular income, it is important to watch out for dividend stocks.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dividend Kings Down Today: Why Johnson & Johnson (JNJ), Coca-Cola (KO) and Procter & Gamble (PG) Are Sliding
Some analysts expect Procter & Gamble to cut its forecast thanks to uncertainty over spending with global trade tensions.
